dc.contributor.author | Fassan, M | |
dc.contributor.author | Cui, R | |
dc.contributor.author | Gasparini, P | |
dc.contributor.author | Mescoli, C | |
dc.contributor.author | Guzzardo, V | |
dc.contributor.author | Vicentini, C | |
dc.contributor.author | Munari, G | |
dc.contributor.author | Loupakis, F | |
dc.contributor.author | Lonardi, S | |
dc.contributor.author | Braconi, C | |
dc.contributor.author | Scarpa, M | |
dc.contributor.author | D'Angelo, E | |
dc.contributor.author | Pucciarelli, S | |
dc.contributor.author | Angriman, I | |
dc.contributor.author | Agostini, M | |
dc.contributor.author | D'Incá, R | |
dc.contributor.author | Farinati, F | |
dc.contributor.author | Gafà, R | |
dc.contributor.author | Lanza, G | |
dc.contributor.author | Frankel, WL | |
dc.contributor.author | Croce, CM | |
dc.contributor.author | Valeri, N | |
dc.contributor.author | Rugge, M | |
dc.date.accessioned | 2019-04-18T08:43:10Z | |
dc.date.issued | 2019-02-01 | |
dc.identifier.citation | Translational oncology, 2019, 12 (2), pp. 282 - 291 | |
dc.identifier.issn | 1936-5233 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3192 | |
dc.identifier.eissn | 1936-5233 | |
dc.identifier.doi | 10.1016/j.tranon.2018.10.013 | |
dc.description.abstract | miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors. | |
dc.format | Print-Electronic | |
dc.format.extent | 282 - 291 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-10-31 | |
rioxxterms.versionofrecord | 10.1016/j.tranon.2018.10.013 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2019-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Translational oncology | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
pubs.publication-status | Published | |
pubs.volume | 12 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Signal Transduction & Molecular Pharmacology | |
icr.researchteam | Gastrointestinal Cancer Biology and Genomics | |
dc.contributor.icrauthor | Braconi, Chiara | |
dc.contributor.icrauthor | Valeri, Nicola | |